Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Operating Expenses for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 13.61% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $7.5 billion (down 36.36% YoY), while the FY2025 annual figure was $7.8 billion, down 30.44% from the prior year.
• Operating Expenses came in at $1.8 billion for Q1 2026 at Vertex Pharmaceuticals, down from $2.0 billion in the prior quarter.
• The five-year high for Operating Expenses was $6.2 billion in Q2 2024, with the low at $1.1 billion in Q1 2022.
• Average Operating Expenses over 5 years is $1.9 billion, with a median of $1.6 billion recorded in 2023.
• Across the five-year window, Operating Expenses soared 319.98% in 2024 and sank 70.56% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $1.3 billion in 2022, then climbed by 20.49% to $1.5 billion in 2023, then advanced by 23.33% to $1.9 billion in 2024, then gained by 5.2% to $2.0 billion in 2025, then retreated by 6.82% to $1.8 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $1.8 billion, $2.0 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.